Accelerating stem cell trials for Alzheimer's disease.
Abstract
At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic
treatments are modestly effective and offer only temporary benefit. Advances in induced
pluripotent stem cell (iPSC) technology have the potential to enable development of
so-called disease-in-a-dish personalised models to study disease mechanisms and reveal
new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential
drug candidates. Different cell types can also be produced for therapeutic use. In
2015, the US Food and Drug Administration granted investigational new drug approval
for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells
to treat Alzheimer's disease in the USA. Similar trials are either underway or being
planned in Europe and Asia. Although safety and ethical concerns remain, we call for
the acceleration of human stem cell-based translational research into the causes and
potential treatments of Alzheimer's disease.
Type
Journal articleSubject
HumansAlzheimer Disease
Mesenchymal Stem Cell Transplantation
Clinical Trials as Topic
Induced Pluripotent Stem Cells
Permalink
https://hdl.handle.net/10161/24635Published Version (Please cite this version)
10.1016/s1474-4422(15)00332-4Publication Info
(2016). Accelerating stem cell trials for Alzheimer's disease. The Lancet. Neurology, 15(2). pp. 219-230. 10.1016/s1474-4422(15)00332-4. Retrieved from https://hdl.handle.net/10161/24635.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
P. Murali Doraiswamy
Professor of Psychiatry and Behavioral Sciences
Murali Doraiswamy MBBS FRCP is Professor of Psychiatry and Professor in Medicine at
Duke University School of Medicine where he is a highly cited physician scientist
at the Duke Institute for Brain Sciences. He is also a Senior Fellow at the Duke
Center for the Study of Aging and an Affiliate Faculty at the Duke Center for Precision
Medicine and Applied Genomics as well as the Duke Microbiome Center. He directs a
clinical trials unit that has been involved in the development of ma
Joanne Kurtzberg
Jerome S. Harris Distinguished Professor of Pediatrics
Dr. Kurtzberg is an internationally renowned expert in pediatric hematology/oncology,
pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation,
and novel applications of cord blood and birthing tissues in the emerging fields of
cellular therapies and regenerative medicine. Dr. Kurtzberg serves as the Director
of the Marcus Center for Cellular Cures (MC3), Director of the Pediatric Transplant
and Cellular Therapy Program, Director of the Carolina
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info